These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 26367725)

  • 21. CD39 positive regulatory T cell frequency as a biomarker of treatment response to methotrexate in rheumatoid arthritis.
    Gupta V; Katiyar S; Singh A; Misra R; Aggarwal A
    Int J Rheum Dis; 2018 Aug; 21(8):1548-1556. PubMed ID: 30146748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphism of genes involved in methotrexate pathway: Predictors of response to methotrexate therapy in Indian rheumatoid arthritis patients.
    Singh A; Gangadharan H; Gupta V; Patro PS; Misra R; Aggarwal A
    Int J Rheum Dis; 2021 May; 24(5):654-662. PubMed ID: 33780152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No correlation between MTHFR c.677 C > T, MTHFR c.1298 A > C, and ABCB1 c.3435 C > T polymorphisms and methotrexate therapeutic outcome of rheumatoid arthritis in West Algerian population.
    Boughrara W; Benzaoui A; Aberkane M; Moghtit FZ; Dorgham S; Lardjam-Hetraf AS; Ouhaibi-Djellouli H; Teixeira EP; Boudjema A
    Inflamm Res; 2017 Jun; 66(6):505-513. PubMed ID: 28299396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.
    Wessels JA; van der Kooij SM; le Cessie S; Kievit W; Barerra P; Allaart CF; Huizinga TW; Guchelaar HJ;
    Arthritis Rheum; 2007 Jun; 56(6):1765-75. PubMed ID: 17530705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy.
    van der Heijde D; Burmester G; Melo-Gomes J; Codreanu C; Mola EM; Pedersen R; Freundlich B; Chang DJ;
    Ann Rheum Dis; 2008 Feb; 67(2):182-8. PubMed ID: 17728331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients.
    Samara SA; Irshaid YM; Mustafa KN
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):746-55. PubMed ID: 25074866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation.
    Senapati S; Singh S; Das M; Kumar A; Gupta R; Kumar U; Jain S; Juyal RC; Thelma BK
    Pharmacogenet Genomics; 2014 Apr; 24(4):211-9. PubMed ID: 24583629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation.
    Aggarwal P; Naik S; Mishra KP; Aggarwal A; Misra R
    Indian J Med Res; 2006 Nov; 124(5):521-6. PubMed ID: 17213520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis.
    Hobl EL; Mader RM; Erlacher L; Duhm B; Mustak M; Bröll H; Högger P; Kalipciyan M; Jilma B
    Clin Exp Rheumatol; 2011; 29(6):963-9. PubMed ID: 22133036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug resistance protein-1 expression, function and polymorphisms in patients with rheumatoid arthritis not responding to methotrexate.
    Prasad S; Tripathi D; Rai MK; Aggarwal S; Mittal B; Agarwal V
    Int J Rheum Dis; 2014 Nov; 17(8):878-86. PubMed ID: 24734954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
    Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
    J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC; Haraoui B; Guérette B; Mozaffarian N; Liu S; Kavanaugh A
    J Rheumatol; 2014 Feb; 41(2):235-43. PubMed ID: 24293583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of association between MTHFR A1298C polymorphism and outcome of methotrexate treatment in rheumatoid arthritis patients: evidence from a systematic review and meta-analysis.
    Fan H; Li Y; Zhang L; Li Y; Li W
    Int J Rheum Dis; 2017 May; 20(5):526-540. PubMed ID: 28544525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
    Bergstra SA; Allaart CF; van den Berg R; Chopra A; Govind N; Huizinga TWJ; Landewe RBM
    Arthritis Res Ther; 2017 Nov; 19(1):258. PubMed ID: 29166919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population.
    Cáliz R; del Amo J; Balsa A; Blanco F; Silva L; Sanmarti R; Martínez FG; Collado MD; Ramirez Mdel C; Tejedor D; Artieda M; Pascual-Salcedo D; Oreiro N; Andreu JL; Graell E; Simon L; Martínez A; Mulero J
    Scand J Rheumatol; 2012 Feb; 41(1):10-4. PubMed ID: 22044028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.